September 2006 Meeting

The Application of Hybrid FTMS Technology
to Accelerate Pharmaceutical Drug Discovery 

The September 2006 CSSC meeting will be held at the Yankee Silversmith Inn in Wallingford, CT.  The meeting will feature a technical presentation by Dr. Mark Sanders of Bristol-Myers Squibb, as well as hors d'oeuvres and a cash bar.  The cost of the meeting is $25 ($15 Students and Emeritus) and is to be paid at the event.

Sorry, but the registration deadline has passed.

To use the online system, you must be registered as a user.
Click here to become a registered user.

Click here for a printable version of this announcement

Abstract:

Mark Sanders, Haiying Zhang, Serhiy Hnatyshyn, Petia Shipkova and Bethanne Warrack

The new generation hybrid linear ion trap FTMS systems (LTQ-FT, LTQ-Orbitrap) provide the much needed bridge between the excellent performance and capabilities of the FT mass spectrometers and the well-established robustness and automation capability of ion traps.  Routine high resolution accurate mass measurements of 2 ppm or less, externally calibrated, provide for rapid approaches to profile both xenobiotic and endogenous metabolites.  By exploiting the mass defect properties of molecules, structurally related compounds (e.g. a drug and its metabolites) can be selectively identified in the presence of complex mixtures. This is proving to be valuable, particularly in the identification of phase II conjugates where the mass defect filter can be more selective than the traditional triple quadrupole precursor ion or neutral loss approaches. Consistent and reliable accurate mass measurements allow us to unambiguously group related ions and comprehensively catalog the components that can then be reliably tracked and quantitated. This methodology, originally developed for our metabolomics efforts, is also proving useful in xenobiotic drug metabolism studies. In the LC/MS profile of rat urine, which might contain tens of thousands of ions, a single component may have many ions associated with it beyond the expected isotopic distribution, e.g. >12 related pseudo-molecular ions for hippuric acid. Working at the component level the detection of changes between dosed and control samples becomes more straightforward which is a significant advantage for a drug metabolism study.

Biography:  Mark Sanders, Ph.D., Bristol-Myers Squibb Pharmaceutical Research Institute

Mark is a Senior Principal Scientist and Leader of the Discovery Analytical Sciences MS Group at Bristol Myers Squibb. This core technology group provides analytical support and method development for Discovery Chemistry and Biology and the Pharmaceutical Candidate Optimization and Lead Profiling organizations within BMS. Mark received his B.S. in Chemistry (1983) and Ph.D. in Synthetic Organic Chemistry (1987) from the University of Nottingham in England. After a two year postdoctoral research position with Prof. John Casida at UC Berkley, CA where he studied pesticide metabolism and mode of action, Mark took a staff position within the Pesticide Chemistry and Toxicology Laboratory at UC Berkeley and switched fields from synthetic to analytical chemistry. In 1992 Mark joined Finnigan Corporation in San Jose, CA where he became the Demonstration Lab Manager for the Americas, specializing in applications for ion trap and triple quadrupole instruments. Mark accepted a position within Analytical Research and Development at Bristol-Myers Squibb in Princeton, NJ in 1996 and in 1998 he moved to the newly formed Discovery Analytical Sciences Group as the MS group leader. Mark’s research interests include the development of automated systems and software based on MS technology.

Yankee Silversmith Inn
1033 North Colony Road
Wallingford, CT 06492
(203) 269-5444

Last Updated:  08/23/2006 09:39 AM